Selected research
Industry Research
Low Molecular Weight Heparin API Industry Research Report 2026
Market perspective
The global Low Molecular Weight Heparin API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Low Molecular Weight Heparin API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Low Molecular Weight Heparin API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Low Molecular Weight Heparin API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Low Molecular Weight Heparin API include Yino Pharma, Changzhou Qianhong Biopharma, Nanjing Nanda Pharmaceutical, Qingdao Jiulong Biopharmaceutical, Nanjing King-friend, Hubei Enoray Biopharmaceutical, Shenzhen Hepalink Pharmaceutical, Dongying Tiandong Pharmaceutical and Yantai Dongcheng Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Low Molecular Weight Heparin API market in terms of revenue (US$ million) and, where applicable, sales volume (Billion Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Billion Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Low Molecular Weight Heparin API Market by Company
Yino Pharma
Changzhou Qianhong Biopharma
Nanjing Nanda Pharmaceutical
Qingdao Jiulong Biopharmaceutical
Nanjing King-friend
Hubei Enoray Biopharmaceutical
Shenzhen Hepalink Pharmaceutical
Dongying Tiandong Pharmaceutical
Yantai Dongcheng Pharmaceutical
Cisen Pharmaceutical
Hebei Changshan
Opocrin
Low Molecular Weight Heparin API Segment by Type
Low Molecular Weight Heparin Sodium
Low Molecular Weight Heparin Calcium
Low Molecular Weight Heparin API Segment by Application
Enoxaparin Sodium
Tinzaparin Sodium
Parnaparin Sodium
Nadroparin Calcium
Dalteparin Sodium
Low Molecular Weight Heparin API Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Low Molecular Weight Heparin API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Low Molecular Weight Heparin API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Low Molecular Weight Heparin API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Low Molecular Weight Heparin API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Low Molecular Weight Heparin API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Low Molecular Weight Heparin API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Low Molecular Weight Heparin Sodium
- Low Molecular Weight Heparin Calcium
Applications
- Enoxaparin Sodium
- Tinzaparin Sodium
- Parnaparin Sodium
- Nadroparin Calcium
- Dalteparin Sodium
Companies covered
- Yino Pharma
- Changzhou Qianhong Biopharma
- Nanjing Nanda Pharmaceutical
- Qingdao Jiulong Biopharmaceutical
- Nanjing King-friend
- Hubei Enoray Biopharmaceutical
- Shenzhen Hepalink Pharmaceutical
- Dongying Tiandong Pharmaceutical
- Yantai Dongcheng Pharmaceutical
- Cisen Pharmaceutical
- Hebei Changshan
- Opocrin
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Low Molecular Weight Heparin API Market Size (2021-2032)
- 2.2.2 Global Low Molecular Weight Heparin API Sales (2021-2032)
- 2.2.3 Global Low Molecular Weight Heparin API Market Average Price (2021-2032)
- 2.3 Low Molecular Weight Heparin API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Low Molecular Weight Heparin Sodium
- 2.3.3 Low Molecular Weight Heparin Calcium
- 2.4 Low Molecular Weight Heparin API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Enoxaparin Sodium
- 2.4.3 Tinzaparin Sodium
- 2.4.4 Parnaparin Sodium
- 2.4.5 Nadroparin Calcium
- 2.4.6 Dalteparin Sodium
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Low Molecular Weight Heparin API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Low Molecular Weight Heparin API Sales (Billion Units) of Manufacturers (2021-2026)
- 3.3 Global Low Molecular Weight Heparin API Revenue of Manufacturers (2021-2026)
- 3.4 Global Low Molecular Weight Heparin API Average Price by Manufacturers (2021-2026)
- 3.5 Global Low Molecular Weight Heparin API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Low Molecular Weight Heparin API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Low Molecular Weight Heparin API, Product Type & Application
- 3.8 Global Manufacturers of Low Molecular Weight Heparin API, Established Date
- 3.9 Global Low Molecular Weight Heparin API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Yino Pharma
- 4.1.1 Yino Pharma Company Information
- 4.1.2 Yino Pharma Business Overview
- 4.1.3 Yino Pharma Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Yino Pharma Low Molecular Weight Heparin API Product Portfolio
- 4.1.5 Yino Pharma Recent Developments
- 4.2 Changzhou Qianhong Biopharma
- 4.2.1 Changzhou Qianhong Biopharma Company Information
- 4.2.2 Changzhou Qianhong Biopharma Business Overview
- 4.2.3 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Changzhou Qianhong Biopharma Low Molecular Weight Heparin API Product Portfolio
- 4.2.5 Changzhou Qianhong Biopharma Recent Developments
- 4.3 Nanjing Nanda Pharmaceutical
- 4.3.1 Nanjing Nanda Pharmaceutical Company Information
- 4.3.2 Nanjing Nanda Pharmaceutical Business Overview
- 4.3.3 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Nanjing Nanda Pharmaceutical Low Molecular Weight Heparin API Product Portfolio
- 4.3.5 Nanjing Nanda Pharmaceutical Recent Developments
- 4.4 Qingdao Jiulong Biopharmaceutical
- 4.4.1 Qingdao Jiulong Biopharmaceutical Company Information
- 4.4.2 Qingdao Jiulong Biopharmaceutical Business Overview
- 4.4.3 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Qingdao Jiulong Biopharmaceutical Low Molecular Weight Heparin API Product Portfolio
- 4.4.5 Qingdao Jiulong Biopharmaceutical Recent Developments
- 4.5 Nanjing King-friend
- 4.5.1 Nanjing King-friend Company Information
- 4.5.2 Nanjing King-friend Business Overview
- 4.5.3 Nanjing King-friend Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Nanjing King-friend Low Molecular Weight Heparin API Product Portfolio
- 4.5.5 Nanjing King-friend Recent Developments
- 4.6 Hubei Enoray Biopharmaceutical
- 4.6.1 Hubei Enoray Biopharmaceutical Company Information
- 4.6.2 Hubei Enoray Biopharmaceutical Business Overview
- 4.6.3 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hubei Enoray Biopharmaceutical Low Molecular Weight Heparin API Product Portfolio
- 4.6.5 Hubei Enoray Biopharmaceutical Recent Developments
- 4.7 Shenzhen Hepalink Pharmaceutical
- 4.7.1 Shenzhen Hepalink Pharmaceutical Company Information
- 4.7.2 Shenzhen Hepalink Pharmaceutical Business Overview
- 4.7.3 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Shenzhen Hepalink Pharmaceutical Low Molecular Weight Heparin API Product Portfolio
- 4.7.5 Shenzhen Hepalink Pharmaceutical Recent Developments
- 4.8 Dongying Tiandong Pharmaceutical
- 4.8.1 Dongying Tiandong Pharmaceutical Company Information
- 4.8.2 Dongying Tiandong Pharmaceutical Business Overview
- 4.8.3 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Dongying Tiandong Pharmaceutical Low Molecular Weight Heparin API Product Portfolio
- 4.8.5 Dongying Tiandong Pharmaceutical Recent Developments
- 4.9 Yantai Dongcheng Pharmaceutical
- 4.9.1 Yantai Dongcheng Pharmaceutical Company Information
- 4.9.2 Yantai Dongcheng Pharmaceutical Business Overview
- 4.9.3 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Yantai Dongcheng Pharmaceutical Low Molecular Weight Heparin API Product Portfolio
- 4.9.5 Yantai Dongcheng Pharmaceutical Recent Developments
- 4.10 Cisen Pharmaceutical
- 4.10.1 Cisen Pharmaceutical Company Information
- 4.10.2 Cisen Pharmaceutical Business Overview
- 4.10.3 Cisen Pharmaceutical Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Cisen Pharmaceutical Low Molecular Weight Heparin API Product Portfolio
- 4.10.5 Cisen Pharmaceutical Recent Developments
- 4.11 Hebei Changshan
- 4.11.1 Hebei Changshan Company Information
- 4.11.2 Hebei Changshan Business Overview
- 4.11.3 Hebei Changshan Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hebei Changshan Low Molecular Weight Heparin API Product Portfolio
- 4.11.5 Hebei Changshan Recent Developments
- 4.12 Opocrin
- 4.12.1 Opocrin Company Information
- 4.12.2 Opocrin Business Overview
- 4.12.3 Opocrin Low Molecular Weight Heparin API Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Opocrin Low Molecular Weight Heparin API Product Portfolio
- 4.12.5 Opocrin Recent Developments
5 Global Low Molecular Weight Heparin API Market Scenario by Region
- 5.1 Global Low Molecular Weight Heparin API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Low Molecular Weight Heparin API Sales by Region: 2021-2032
- 5.2.1 Global Low Molecular Weight Heparin API Sales by Region: 2021-2026
- 5.2.2 Global Low Molecular Weight Heparin API Sales by Region: 2027-2032
- 5.3 Global Low Molecular Weight Heparin API Revenue by Region: 2021-2032
- 5.3.1 Global Low Molecular Weight Heparin API Revenue by Region: 2021-2026
- 5.3.2 Global Low Molecular Weight Heparin API Revenue by Region: 2027-2032
- 5.4 North America Low Molecular Weight Heparin API Market Facts & Figures by Country
- 5.4.1 North America Low Molecular Weight Heparin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Low Molecular Weight Heparin API Sales by Country (2021-2032)
- 5.4.3 North America Low Molecular Weight Heparin API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Low Molecular Weight Heparin API Market Facts & Figures by Country
- 5.5.1 Europe Low Molecular Weight Heparin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Low Molecular Weight Heparin API Sales by Country (2021-2032)
- 5.5.3 Europe Low Molecular Weight Heparin API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Low Molecular Weight Heparin API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Low Molecular Weight Heparin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Low Molecular Weight Heparin API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Low Molecular Weight Heparin API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Low Molecular Weight Heparin API Market Facts & Figures by Country
- 5.7.1 South America Low Molecular Weight Heparin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Low Molecular Weight Heparin API Sales by Country (2021-2032)
- 5.7.3 South America Low Molecular Weight Heparin API Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Low Molecular Weight Heparin API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Low Molecular Weight Heparin API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Low Molecular Weight Heparin API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Low Molecular Weight Heparin API Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Low Molecular Weight Heparin API Sales by Type (2021-2032)
- 6.1.1 Global Low Molecular Weight Heparin API Sales by Type (2021-2032) & (Billion Units)
- 6.1.2 Global Low Molecular Weight Heparin API Sales Market Share by Type (2021-2032)
- 6.2 Global Low Molecular Weight Heparin API Revenue by Type (2021-2032)
- 6.2.1 Global Low Molecular Weight Heparin API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Low Molecular Weight Heparin API Revenue Market Share by Type (2021-2032)
- 6.3 Global Low Molecular Weight Heparin API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Low Molecular Weight Heparin API Sales by Application (2021-2032)
- 7.1.1 Global Low Molecular Weight Heparin API Sales by Application (2021-2032) & (Billion Units)
- 7.1.2 Global Low Molecular Weight Heparin API Sales Market Share by Application (2021-2032)
- 7.2 Global Low Molecular Weight Heparin API Revenue by Application (2021-2032)
- 7.2.1 Global Low Molecular Weight Heparin API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Low Molecular Weight Heparin API Revenue Market Share by Application (2021-2032)
- 7.3 Global Low Molecular Weight Heparin API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Low Molecular Weight Heparin API Value Chain Analysis
- 8.1.1 Low Molecular Weight Heparin API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Low Molecular Weight Heparin API Production Mode & Process
- 8.2 Low Molecular Weight Heparin API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Low Molecular Weight Heparin API Distributors
- 8.2.3 Low Molecular Weight Heparin API Customers
9 Global Low Molecular Weight Heparin API Analyzing Market Dynamics
- 9.1 Low Molecular Weight Heparin API Industry Trends
- 9.2 Low Molecular Weight Heparin API Industry Drivers
- 9.3 Low Molecular Weight Heparin API Industry Opportunities and Challenges
- 9.4 Low Molecular Weight Heparin API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst